Goldman Sachs Group Inc. Takes $446,000 Position in Nuvectis Pharma, Inc. $NVCT

Key Points

• Goldman Sachs Group Inc. acquired approximately 45,608 shares of Nuvectis Pharma, valued at about $446,000, representing a 0.22% stake in the company.
• Several large investors, including Baldwin Wealth Partners LLC and Oppenheimer & Co. Inc., have increased their holdings in Nuvectis Pharma, indicating growing institutional interest.
• Recent analyst ratings on Nuvectis Pharma reflect mixed sentiments, with Wall Street Zen downgrading the stock to a "sell" while HC Wainwright maintains a "buy" rating but lowers its price target from $15.00 to $10.00.

Goldman Sachs Group Inc. acquired a new stake in Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 45,608 shares of the company's stock, valued at approximately $446,000. Goldman Sachs Group Inc. owned approximately 0.22% of Nuvectis Pharma as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in NVCT. Baldwin Wealth Partners LLC MA grew its holdings in Nuvectis Pharma by 0.7% during the first quarter. Baldwin Wealth Partners LLC MA now owns 358,461 shares of the company's stock valued at $3,502,000 after purchasing an additional 2,500 shares during the last quarter. Blue Zone Wealth Advisors LLC acquired a new position in Nuvectis Pharma in the 1st quarter valued at $102,000. Northern Trust Corp raised its holdings in Nuvectis Pharma by 68.7% in the 4th quarter. Northern Trust Corp now owns 25,725 shares of the company's stock worth $139,000 after acquiring an additional 10,472 shares during the period. Oppenheimer & Co. Inc. raised its holdings in Nuvectis Pharma by 64.0% in the 1st quarter. Oppenheimer & Co. Inc. now owns 41,000 shares of the company's stock worth $401,000 after acquiring an additional 16,000 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in Nuvectis Pharma during the 4th quarter worth $103,000. Institutional investors own 96.77% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on NVCT. Wall Street Zen lowered shares of Nuvectis Pharma from a "hold" rating to a "sell" rating in a research report on Sunday, June 29th. HC Wainwright cut their price objective on shares of Nuvectis Pharma from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Monday, August 4th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $15.33.

Nuvectis Pharma Price Performance

Nuvectis Pharma stock opened at $6.08 on Friday. The business has a 50 day simple moving average of $6.64 and a 200 day simple moving average of $8.12. The company has a market capitalization of $154.78 million, a PE ratio of -5.20 and a beta of -0.27. Nuvectis Pharma, Inc. has a one year low of $4.44 and a one year high of $11.80.

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.05). Equities analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 earnings per share for the current fiscal year.

Nuvectis Pharma Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.